GlassScriptPhysician profile
Nicole Alexander
NPI 1508397043
$13,563.69
in general payments reported to CMS, 2019-2025
53 companies · $2,712 in 2025
The $2,712 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $280 · 2021: $1,513 · 2022: $2,473 · 2023: $2,750 · 2024: $3,121 · 2025: $2,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,523 · Education: $59.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,522.50 |
| Education | $59.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,431.26 | 2019-2025 | Qulipta, Ubrelvy, Botox |
| Emd Serono, INC. | $1,254.76 | 2020-2025 | Mavenclad, Mavenclad |
| Lilly USA, LLC | $729.39 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Biogen, INC. | $658.28 | 2021-2025 | Vumerity, Tysabri |
| Genentech USA, INC. | $615.81 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Pfizer INC. | $567.50 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $504.99 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $461.70 | 2019-2025 | Ultomiris, Soliris |
| Mdd US Operations, LLC | $448.39 | 2021-2025 | Gocovri, Gocovri |
| Teva Pharmaceuticals USA, INC. | $442.77 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Sk Life Science, INC. | $429.79 | 2021-2025 | |
| Ucb, INC. | $404.41 | 2022-2025 | Briviact, Zilbrysq, Rystiggo |
| Neurocrine Biosciences, INC. | $350.41 | 2020-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $336.78 | 2019-2025 | Crexont, Rytary, Lyvispah |
| Lundbeck LLC | $320.03 | 2021-2025 | Vyepti |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.